TTK Healthcare Ltd. Stock Falls to 52-Week Low of Rs.932.2

Stock Price Movement and Market Context

On 12 Feb 2026, TTK Healthcare Ltd. recorded its lowest price in the past year at Rs.932.2, a level not seen since early 2025. Despite outperforming its sector by 0.3% on the day, the stock remains below its 20-day, 50-day, 100-day, and 200-day moving averages, signalling a persistent downward trend. It is, however, trading above its 5-day moving average, indicating some short-term price support.

The broader market environment has been mixed. The Sensex opened 265.21 points lower and was trading at 83,813.29, down 0.5% on the day. Notably, the Sensex is just 2.8% shy of its 52-week high of 86,159.02 and has recorded a 2.79% gain over the past three weeks. However, the index is trading below its 50-day moving average, though the 50DMA remains above the 200DMA, suggesting a cautiously optimistic medium-term outlook for the market overall.

Long-Term Performance and Financial Metrics

TTK Healthcare Ltd.’s stock has underperformed significantly over the last year, delivering a negative return of 22.45%, in stark contrast to the Sensex’s positive 10.03% gain over the same period. The stock’s 52-week high was Rs.1,398.9, highlighting the extent of the decline from its peak.

Over the past five years, the company’s net sales have grown at a modest compound annual growth rate (CAGR) of 6.99%, while operating profit has increased at a rate of 15.42%. These figures indicate restrained growth relative to industry peers and broader market expectations.

Recent Quarterly and Half-Yearly Financial Indicators

The company’s December 2025 quarter results were largely flat, reflecting limited momentum in revenue and profitability. Cash and cash equivalents at the half-year mark stood at Rs.600.89 crores, the lowest level recorded in recent periods, which may indicate tighter liquidity conditions.

Debtors turnover ratio for the half-year was 7.40 times, also the lowest in recent history, suggesting slower collections or extended credit terms. Additionally, non-operating income accounted for 80.43% of profit before tax (PBT) in the quarter, underscoring a reliance on income sources outside core operations.

Shareholding and Market Perception

Despite the company’s sizeable market presence, domestic mutual funds hold a minimal stake of just 0.01%. Given their capacity for detailed research and due diligence, this limited exposure may reflect cautious sentiment regarding the stock’s valuation or business prospects.

TTK Healthcare Ltd. has also underperformed the BSE500 index across multiple timeframes, including the last three years, one year, and three months, reinforcing its relative weakness within the broader market.

Balance Sheet and Valuation Metrics

The company maintains a low average debt-to-equity ratio of zero, indicating a debt-free capital structure. Return on equity (ROE) stands at 6.5%, which, while positive, is modest compared to industry standards.

Valuation-wise, the stock trades at a price-to-book (P/B) ratio of 1.2, which is a premium relative to its peers’ historical averages. This premium valuation is notable given the subdued growth and profitability metrics. Over the past year, profits have increased by a marginal 2.4%, while the price-to-earnings-to-growth (PEG) ratio is elevated at 8.2, signalling that earnings growth has not kept pace with the stock price.

Summary of Key Performance Indicators

TTK Healthcare Ltd. currently holds a Mojo Score of 37.0 with a Mojo Grade of Sell, downgraded from Hold on 21 Jul 2025. The company’s market capitalisation grade is 4, reflecting its mid-tier size within the diversified sector.

The stock’s day change was a decline of 0.21%, consistent with its ongoing downward trajectory. The combination of modest sales growth, limited profit expansion, and valuation premiums relative to peers contributes to the cautious stance reflected in its grading.

Conclusion

TTK Healthcare Ltd.’s stock reaching a 52-week low of Rs.932.2 underscores a period of subdued performance and valuation pressures. While the company maintains a clean balance sheet and some positive return metrics, its growth rates and profitability have not met market expectations. The stock’s relative underperformance against major indices and sector peers highlights the challenges faced in regaining momentum.

Investors and market participants will continue to monitor the company’s financial disclosures and market developments closely as it navigates this phase.

Unlock special upgrade rates for a limited period. Start Saving Now →